Acceleron (XLRN) option implied volatility flat into Phase III Believe results

Acceleron Pharma (NASDAQ: XLRN) July call option implied volatility is at 62, August is at 56; compared to its 52-week range of 37 to 152 into announcing with its partner Celgene (CELG) positive Phase III Believe results for luspatercept in transfusion dependent beta thalassemia.

You May Also Be Interested In

• Explosions heard on Iran's Kharg island - MEHR
• Brookfield Renewable (BEPC) 5100 contracts of September 35 calls trade, share price up 2.8%
• GFL Environmental (GFL) spreader of 17500 contracts of December 45 and 50 calls